BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 17158545)

  • 1. Molecular biology of renal cell cancer and the identification of therapeutic targets.
    Iliopoulos O
    J Clin Oncol; 2006 Dec; 24(35):5593-600. PubMed ID: 17158545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
    Zhang YT; Chen N; Zeng H; Zhou Q
    Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
    [No Abstract]   [Full Text] [Related]  

  • 5. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
    Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
    Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Von hippel-lindau: a tumor suppressor links microtubules to ciliogenesis and cancer development.
    Kuehn EW; Walz G; Benzing T
    Cancer Res; 2007 May; 67(10):4537-40. PubMed ID: 17510376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional significance of erythropoietin in renal cell carcinoma.
    Morais C; Johnson DW; Vesey DA; Gobe GC
    BMC Cancer; 2013 Jan; 13():14. PubMed ID: 23305401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Molecular biology of the clear cell renal cell carcinoma: principles for a selective treatment].
    Grande Pulido E; Martín Centeno A; Maroto Rey P; Solsona Narbón E
    Actas Urol Esp; 2007 Mar; 31(3):233-43. PubMed ID: 17658151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. von Hippel-Lindau tumor suppressor protein regulates the assembly of intercellular junctions in renal cancer cells through hypoxia-inducible factor-independent mechanisms.
    Calzada MJ; Esteban MA; Feijoo-Cuaresma M; Castellanos MC; Naranjo-Suárez S; Temes E; Méndez F; Yánez-Mo M; Ohh M; Landázuri MO
    Cancer Res; 2006 Feb; 66(3):1553-60. PubMed ID: 16452212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism.
    Wu KL; Miao H; Khan S
    Am J Physiol Renal Physiol; 2007 Dec; 293(6):F1836-46. PubMed ID: 17898043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New insights into the biology of renal cell carcinoma.
    Li L; Kaelin WG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):667-86. PubMed ID: 21763962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cilium formation requires von hippel-lindau gene function in renal-derived cells.
    Lutz MS; Burk RD
    Cancer Res; 2006 Jul; 66(14):6903-7. PubMed ID: 16849532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells.
    Peruzzi B; Athauda G; Bottaro DP
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14531-6. PubMed ID: 16983094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.
    David JM; Owens TA; Barwe SP; Rajasekaran AK
    Mol Cancer Ther; 2013 Nov; 12(11):2296-307. PubMed ID: 24006494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.
    Pan J; Mestas J; Burdick MD; Phillips RJ; Thomas GV; Reckamp K; Belperio JA; Strieter RM
    Mol Cancer; 2006 Nov; 5():56. PubMed ID: 17083723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular genetics of familial renal cell carcinoma syndromes.
    Cohen D; Zhou M
    Clin Lab Med; 2005 Jun; 25(2):259-77. PubMed ID: 15848736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene therapy for renal cancer.
    Haviv YS; Curiel DT
    Contrib Nephrol; 2008; 159():135-150. PubMed ID: 18391590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.